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Modifier genes play a significant role in the phenotypic expres-
sion of PKD1.
Background. Polycystic kidney disease type 1 (PKD1) is char-
acterized by extreme variation in the severity and progression of
renal and extrarenal phenotypes. There are significant familial
phenotype differences; but it is not clear if this is due to differ-
ences in PKD1 mutations, differences in genetic background,
or both.
Methods. A total of 315 affected relatives (83 PKD1 families)
without end-stage renal disease (ESRD) were evaluated for dis-
ease markers, including renal volume, creatinine clearance, pro-
teinuria, liver cysts, and hypertension. Of these patients, 19%
progressed to ESRD within 1 to 10 years after the initial ex-
amination. Nested analysis of variance was used to investigate
interfamilial and intrafamilial differences in these phenotypes.
Heritability analyses were used to estimate the effect of the ge-
netic background on phenotypic variability. The age of onset of
ESRD was also analyzed with an additional 389 family mem-
bers from the same PKD1 families without clinical evaluation
but with data on age of onset of ESRD (or age without ESRD).
Results. There were significant phenotype differences be-
tween patients with the same mutation and different genetic
backgrounds. The phenotypic variation between patients with
different mutations and different genetic backgrounds was not
significantly greater than the variation between patients with
the same mutation and different genetic backgrounds. How-
ever, when the 389 family members were included, both the
mutation and modifier genes had significant effects on the age
of onset of ESRD. Inherited differences in genetic background
were estimated to account for 18% to 59% of the phenotypic
variability in PKD1 disease markers in patients prior to ESRD
and in the subsequent progression to ESRD (43% heritability)
in the 315 patients who were clinically evaluated.
Conclusion. Modifier loci in the genetic background are
important factors in inter- and intrafamilial variability in the
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phenotypic expression of PKD1. The extreme intrafamilial phe-
notype differences are consistent with the hypothesis that one
or a few modifier genes have a major effect on the progression
and severity of PKD1.
Autosomal-dominant polycystic kidney disease
(ADPKD) is one of the most common inherited condi-
tions in humans [1]. The disease is caused by a mutation
in either the PKD1 or the PKD2 gene, with PKD1 mu-
tations accounting for over 80% of patients [2]. Multiple
renal epithelial cysts and progressive renal enlargement
are typically present in mutation carriers over 30 years
of age [3]. Beyond these hallmarks of the disease, there
is tremendous variability in the phenotypic expression
of the primary genetic defect in ADPKD. Liver cysts are
the most common extrarenal manifestation, occurring
in at least 75% of patients by age 60 years [4]. Hyper-
tension occurs in 50% to 75% of patients prior to renal
insufficiency, and is thought to accelerate the decline
in renal function [5–10]. Although recent studies have
shown significant slowing of ADPKD renal progression
over the last 2 decades, approximately 50% of ADPKD
patients progress to end-stage renal disease (ESRD)
by age 60 years [7, 10]. The extreme variability in renal
function, presentation of liver cysts and hypertension,
and rate of progression to ESRD has made it difficult
to predict prognosis in individual patients. The factors
contributing to the variability remain largely unknown.
A number of studies have documented significant inter-
familial and intrafamilial phenotype variation in ADPKD
[11–14]. Differences between families are partly due to
locus heterogeneity, with progression to ESRD delayed
by 10 to 20 years in patients with PKD2 mutations com-
pared to patients with PKD1 mutations [14–17]. How-
ever, there are also significant differences in the age at
onset of ESRD amongst PKD1 families. This observa-
tion cannot be explained by locus heterogeneity, since all
of these families harbor mutations in the PKD1 gene. The
observed differences could reflect the diverse spectrum
of defects in PKD1 [13] and/or inherited variation in the
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structure and regulation of genes that modify the effects
of the primary genetic defect [14].
Early studies of PKD1 mutations failed to reveal any
correlation between the characteristics of the molecular
defect and phenotypes in ADPKD; however, several re-
cent studies suggest an association between disease sever-
ity and the position of the mutation in PKD1 [18–20].
With regard to modifier genes, studies in animal mod-
els of PKD have consistently shown that the nature and
severity of renal abnormalities associated with a specific
mutational defect are strongly dependent on the genetic
background in which the mutation is found [21–26]. Lim-
ited data for ADPKD in humans, such as reports of racial
differences in the severity [27], and extreme variation in
severity among relatives with the same mutational defect
[28–30], also support the conclusion that genetic modi-
fiers are an important source of phenotypic variability in
ADPKD. In the present study, we investigate the contri-
butions of mutation diversity and allelic variation in mod-
ifier genes to phenotypic variability using a novel analysis
for separating these effects.
METHODS
Study population
From June 1985 to December 2003, 848 ADPKD sub-
jects from 397 families were recruited for a longitudinal
study of the natural history of ADPKD at the University
of Colorado Health Sciences Center (UCHSC). Patients
who were in ESRD at the time of family contact were ex-
cluded from natural history studies. Blood or mouthwash
DNA samples were obtained for genetic testing for PKD1
and PKD2 markers in affected and at-risk relatives and
their spouses. The criterion for diagnosing ADPKD was
taken as a single renal cyst by ultrasonography in chil-
dren under the age of 18 years and bilateral renal cysts by
ultrasonography in adults [3, 31]. All subjects provided
written informed consent in accordance with protocols
approved by the Colorado Multiple Institutional Review
Board.
Genetic linkage analysis for family classification as
PKD1 or PKD2 was performed in linkage-informative
families using up to 18 polymorphic markers for PKD1
and up to 12 polymorphic markers for PKD2. Multipoint
parametric linkage analysis was performed with Alle-
gro [32] using age-dependent penetrance estimates ob-
tained by age of onset analyses using the Ageon routine
of SAGE [33]. The posterior probability of PKD1 linkage
was calculated as:
P = 0.84 ∗ 10L(PKD1)/[0.84 ∗ 10L(PKD1)
+ 0.14 ∗ 10L(PKD2) + 0.02 ∗ 10]
where L(PKD1) is the logarithm of the odds (LOD) fa-
voring PKD1 linkage and L(PKD2) is the LOD favoring
PKD2 linkage. The formula assumes prior probabilities
of 0.84 and 0.14, respectively, for PKD1 and PKD2 link-
age, and allows for the possibility of a third ADPKD locus
in 0.02 of families. The criterion for classifying a family
as PKD1 by linkage analysis was taken as P > 0.97. Sev-
enty families met this criterion. Fifteen additional families
were classified as PKD1 based on previous [18] and ongo-
ing (unpublished) screening for mutations in the PKD1
gene (Table 1).
A total of 315 PKD1-affected relatives from 83 fami-
lies participated in natural history studies. None of these
patients required renal replacement therapy at the time
of enrollment and testing as part of the natural history
study, which involved a 2-day visit at the UCHSC General
Clinical Research Center (GCRC). Complete physical
examinations were performed on each participant, blood
pressure was measured by a trained nurse, blood samples
were drawn for serum chemistries, 24-hour urine sam-
ples were collected, family and medical histories were ob-
tained, and renal and liver ultrasound examinations were
performed in the UCHSC Radiology Center. Follow-up
studies to determine subsequent development of hyper-
tension or progression to ESRD were conducted by tele-
phone interviews and mail-in questionnaires. Another
389 relatives from these same families were not enrolled
in the natural history studies and therefore did not have
data from a GCRC visit. Of these 389 patients, 180 (46%)
had reached ESRD. The age of onset of ESRD was ana-
lyzed both with and without these relatives.
Phenotype definitions
Serum creatinine, creatinine clearance, urinary protein
excretion, renal volume, and the presence/absence and
number of liver cysts were assessed during the 2-day clinic
visit. The presence/absence and age at diagnosis of hyper-
tension was determined at the time of the clinic visit, or
upon follow-up for patients who were initially normoten-
sive. All of the information on subsequent progression to
ESRD for these patients was obtained after the initial
clinic visit.
Renal volume was defined as the mean of both kid-
neys and was calculated using a standard formula for a
modified ellipsoid for each kidney as follows:
renal volume = 43p ×
(
anteroposterior diameter
4
+ width4
)2
× length2 .
The presence of liver cysts at a given age was deter-
mined by ultrasound. Liver cyst phenotypes were de-
fined as the presence/absence or number (0, 1 to 5, 6
to 15, >15 cysts) of liver cysts at the time of examina-
tion. Urinary protein concentrations were determined
by the Coumassie blue dye-binding method. The mean
of two collections was taken as the level of proteinuria
(mg/24 hours). A serum creatinine measurement and
two consecutive 24-hour urine collections were obtained
for determination of creatinine clearance normalized to
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Table 1. Summary of family sizes and structures, and documentation for classifying 83 PKD1 families
Family size
Number of sibships Number of affected Number with ESRD
PKD1 documentation
Linkageb or mutation
Family number ≥1 affected ≥1 examined Total Examined Total Examineda [L (PKD1); L (PKD2)]
24 3 2 8 7 1 0 0.99 (1.93; −2.99)
41 3 2 6 3 0 0 0.99 (0.93; −4.14)
43 6 4 10 8 1 0 0.99 (3.44; −5.72)
45 6 4 11 6 2 1 0.99 (2.16; −1.05)
46 4 3 6 3 1 0 R2392Pc
47 4 3 9 4 4 1 0.99 (3.63; −6.93)
62 6 4 9 5 4 1 0.99 (1.79; −1.83)
68 5 3 9 5 3 2 0.99 (1.95; ND)
72 3 3 6 5 2 1 0.99 (1.2; −4.76)
73 3 2 4 3 1 1 0.99 (1.32; −1.83)
74 8 4 11 5 3 1 0.99 (1.13; ND)
76 8 5 15 6 5 1 0.99 (2.6; ND)
82 4 2 6 4 2 1 0.99 (2.17; −2.16)
84 1 1 2 1 0 0 1671stopd
91 4 2 9 4 3 1 0.99 (1.27; −0.74)
98 6 4 10 5 4 2 0.99 (1.44; −1.25)
100 3 2 5 3 3 1 0.99 (0.81; −0.46)
109 15 12 32 17 12 3 0.99 (2.79; −5.26)
110 10 5 16 5 4 0 0.99 (1.32; ND)
119 3 2 4 2 3 1 0.98 (0.89; ND)
120 2 1 2 1 2 1 1306stopd
121 3 2 4 2 2 0 0.99 (1.04; −1.06)
124 3 2 6 4 1 0 0.99 (0.98; ND)
125 7 3 10 4 5 2 0.99 (3.16; −5.20)
138 4 3 6 3 2 2 1671stopc
165 5 3 16 6 9 2 0.99 (2.73; −1.34)
174 3 1 5 2 0 0 0.99 (1.14; −0.21)
177 5 3 8 3 0 0 0.99 (0.6; −1.64)
186 3 2 3 2 2 1 Y1517Xd
192 2 1 7 5 2 1 0.99 (1.67; −1.35)
205 5 3 8 4 3 1 0.99 (0.71; −0.66)
256 4 2 6 3 3 0 0.99 (1.58; −2.68)
290 3 1 4 1 1 0 0.99 (1.48; −1.41)
294 5 3 8 4 4 2 0.99 (3.43; −3.44)
344 4 3 8 3 7 2 0.99 (0.86; −0.77)
349 5 2 9 3 3 1 0.99 (0.90; −2.13)
362 7 4 9 5 4 1 0.99 (1.39; ND)
371 4 2 8 4 3 3 0.98 (1.04; ND)
375 3 1 5 2 4 2 0.98 (0.53; −0.49)
386 5 2 6 2 3 0 Q3738Xd
435 7 1 8 1 6 1 0.98 (1.06; 0.23)
459 3 3 5 5 0 0 0.99 (0.71; −0.66)
474 4 3 7 3 3 1 0.99 (1.27; ND)
519 4 3 7 5 0 0 S2423Fc
523 3 2 6 4 1 1 0.98 (0.54; −0.56)
524 5 3 10 5 1 0 0.99 (2.35; −4.06)
525 3 2 7 6 0 0 0.99 (1.92; −1.99)
531 3 2 4 3 2 1 0.99 (1.36; −0.99)
558 5 3 9 7 1 1 0.99 (2.33; −1.60)
576 4 3 4 3 2 2 0.99 (0.83; −1.37)
579 13 5 31 6 8 1 0.99 (2.70; −2.66)
581 9 1 17 1 8 1 Q3701Xd
584 3 2 6 5 1 0 0.99 (1.12; −1.27)
586 2 2 3 3 0 0 0.99 (0.30; −1.72)
588 4 3 13 5 5 1 0.99 (1.39; ND)
591 8 6 9 7 2 1 0.99 (2.12; −2.29)
834 4 3 6 4 2 1 0.99 (1.97; −4.13)
1015 3 2 4 3 3 2 0.99 (0.30; −2.20)
1167 5 3 9 4 2 0 0.99 (1.50; −0.62)
1202 2 2 2 2 0 0 L3510Vd
1203 1 1 1 1 0 0 1365stopd
1205 4 1 10 4 6 2 0.99 (0.60; −0.81)
1245 4 2 7 3 0 0 0.99 (0.25; −2.23)
1283 8 3 12 3 4 1 0.99 (0.38; −3.13)
1296 3 1 4 1 3 1 1671stopd
1308 4 3 8 6 2 1 0.99 (1.51; 0.16)
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Table 1. (Continued)
1313 9 2 20 3 9 0 0.99 (1.72; −0.89)
1334 4 2 7 2 5 1 1671stopc
1347 4 2 4 2 1 0 0.99 (1.19; −0.76)
1348 4 2 7 4 1 0 0.99 (0.82; −0.54)
1350 6 2 10 3 6 1 1671stopd
1359 16 2 26 3 7 0 0.99 (1.37; −3.72)
1732 4 2 6 3 1 0 0.99 (1.15; −3.23)
1757 4 1 6 2 3 0 0.99 (0.63; −2.03)
1816 6 2 13 3 4 0 0.99 (0.35; −2.72)
1884 4 2 9 3 2 0 0.97 (0.74; ND)
1915 5 1 9 2 4 0 0.99 (0.59; −2.08)
2356 2 1 3 2 1 0 0.99 (0.11; −2.21)
2421 5 2 12 3 4 1 0.99 (0.30; −2.21)
2440 4 2 9 6 3 0 0.99 (0.80; −2.73)
2874 2 2 5 5 0 0 0.99 (0.90; −1.53)
2888 2 1 8 2 5 0 0.99 (0.29; −2.14)
2967 5 3 7 3 2 0 0.99 (0.30; −2.14)
ESRD is end-stage renal disease.
aReported to have developed ESRD 1 to 10 years subsequent to the clinic visit for the natural history study.
bND is not done; information for all affected and unaffected relatives was included in linkage analyses.
cWatnick et al, 1999 [18].
dThis laboratory.
1.73 m2 body surface area. Hypertension was defined as
blood pressure ≥140/90 mm Hg, a history of hyperten-
sion, or taking antihypertensive medication. ESRD was
defined as the time of starting chronic dialysis treatment
or receiving a renal transplant.
Age of onset phenotypes were defined in two ways.
The first definition applied only to PKD1-affected rela-
tives who had developed the condition or “event” (hy-
pertension or ESRD). Age at onset was taken as the
age at which hypertension or ESRD first occurred. Using
this definition, the age at onset phenotype for event-free
PKD1-affected relatives is considered unknown. The ex-
clusion of the event-free relatives results in a truncated
sample, which, in addition to reducing statistical power,
may bias results. Therefore, a second phenotype was de-
fined by fitting the marginal distribution of age at on-
set via a semiparametric model [34] implemented in the
SAS procedure PHREG [35]. The PHREG procedure
was used to fit a Cox proportional hazard model to age
of diagnosis of hypertension and age of onset of ESRD,
with gender included as a covariate. Based on a Wald
chi-square test, these data were consistent with the as-
sumption of proportional hazards. Martingale residuals
from Cox regression were used as quantitative traits as
described by others [36–38]. For the Cox model, the mar-
tingale residual for the ith subject with observation time
ti and event status di, where di = 0 if ti is a censored time
or 1 if ti is an event time, is:
M̂i = di − ̂0(ti) exp (b̂ ′zi)
where ̂0(t) is the cumulative baseline hazard function
evaluated at the age of onset of the event or, for event-
free relatives, at the age at last examination [35].
The martingale residual for each subject was used as a
score representing the liability of developing the pheno-
type by time (t). For example, an individual who devel-
oped hypertension at 19 years of age, or 14 years younger
than the median age at diagnosis of hypertension (age
33 years), would have a positive score (0.937), whereas
an individual who was still normotensive at age 55 years,
or 22 years older than the median age at diagnosis of
hypertension, would have a negative score (−1.66).
Statistical analyses
Analysis of variance (ANOVA) and heritability analy-
ses were performed on eight different phenotypes: serum
creatinine, creatinine clearance, urinary protein excre-
tion, renal volume, presence/absence of liver cysts, num-
ber of liver cysts, age at diagnosis of hypertension, and age
of onset of ESRD. The analyses were performed on each
variable using gender, and, when appropriate, age at ex-
amination as covariates. Family and sibship within family
were treated as random effects. Normalizing power trans-
formations were performed to reduce skewness and/or
kurtosis in the distributions of the variables, using the
NOCOM computer program [39] to calculate the max-
imum likelihood estimate of the exponent, p. Statistical
analyses were performed using the transformed variables,
xp, for each variable, x.
Two different ANOVA models were considered. The
model 1 ANOVA takes the form:
Y = l + fi + rj(i);
where fi represents the effects of family i, and rj(i) repre-
sents the effects of relative j within family i. The model 2
ANOVA takes the form:
Y = l + fi + sj(i) + pk(ij);
where sj(i) represents the effects of sibship j within family i
and pk(ij) represents the effects of person k within sibship j
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Table 2. Disease markers and outcomes in natural history studies of
315 patients without end-stage renal disease (ESRD), and
characteristics of the study population
Males Females P value
Number 127 188
Natural history studiesa
Age at visit years 33 ± 16 35 ± 16 NS
Renal volume cm3 783 ± 621 596 ± 458 <0.005
Serum creatinine
concentration mg/dL
1.8 ± 1.4 1.3 ± 1.0 <0.005
Creatinine clearance
mL/min/1.73 m2
86 ± 42 82 ± 37 NS
Urinary protein
excretion mg/24 hours
288 ± 448 228 ± 349 NS
No liver cysts % 55 50
≥1 Liver cysts % 45 50 NS
1 to 5 Liver cysts % 15 17
6 to 15 Liver cysts % 13 11
>15 Liver cysts % 17 23
Age at last follow-up yearsb 37 ± 17 38 ± 17
Progressing to ESRD % 22 18 NS
Age at onset of 50 ± 9 54 ± 11 NS
ESRD years (N = 28) (N = 33)
Presenting with
hypertensionc %
67 53 <0.05
Age at diagnosis of 31 ± 11 35 ± 13 <0.05
hypertension years (N = 85) (N = 100)
aNo patient was in ESRD at the time of the clinic visit.
bFor subjects who progressed to ESRD, this is the age of onset of ESRD.
For subjects who did not progress ESRD, this is the age when we were last
informed that the patient had not reached ESRD (or age at death in the absence
of ESRD).
cHypertension may have been diagnosed before, during, or after the clinic visit.
and family i. Maximum likelihood estimators of the mean
squares corresponding to different variance components
were obtained using the GLM procedure in SAS [35]. Sig-
nificance levels were determined assuming F distributions
for the F ratios comparing between- and within-family
mean squares (family effect) in model 1, and for the
F ratios comparing between-family and between-sibship
mean squares (mutation effect) and comparing between-
and within-sibship mean squares (modifier gene effect)
in model 2.
Heritability (broad sense) is defined as the ratio of the
genetic component of variation to total phenotypic varia-
tion. Heritability analyses in the present context provide
estimates of the contribution to phenotypic variability of
modifying effects in the genetic background. Heritability
estimates were calculated using SOLAR, [40] with age
and gender included as covariates. All PKD1-affected rel-
atives within a family were connected through their com-
mon ancestors in this analysis; however, all phenotypes
for affected relatives who did not participate in natural
history studies, and phenotypes for unaffected spouses,
were coded as unknown.
RESULTS
Characteristics of the family resource
A detailed description of the patient and family re-
source and documentation of their classification as PKD1
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Fig. 1. Survival time to end-stage renal disease (ESRD). The study in-
cluded 315 patients with autosomal-dominant polycystic kidney disease
(ADPKD) from 83 PKD1 families enrolled in natural history studies
at the University of Colorado between 1985 and 2003 (Cohort A, thick
line) and 389 relatives from the same families not evaluated clinically
(Cohort B, thin line). The survival distributions were significantly dif-
ferent (P < 0.005). Upper confidence limits of cohort A and lower
confidence limits of cohort B are shown as dotted lines.
are shown in Table 1. Family sizes ranged from one to 32
total affected relatives, of which one to 17 affected rela-
tives per family were examined in natural history studies.
There were one to 16 sibships per family with at least one
affected relative, and one to 12 sibships in which at least
one affected relative was examined.
Characteristics of the study population are shown in
Table 2 and in Figures 1 and 2. None of the 315 affected
relatives (cohort A) enrolled in natural history studies
had renal failure at the time of their examination; how-
ever, 61 (19%) progressed to ESRD within 1 to 10 years
following their examination, at a median age of 61 years.
The 389 additional relatives (cohort B) were older than
the clinically evaluated subjects (mean year of birth 1940
versus 1961), with 180 (46%) having reached ESRD at
a median age of 56 years. Kaplan-Meier renal survival
curves for the two populations are shown in Figure 1. The
5-year difference in median survival between younger
and older cohorts from the same families is consistent
with previous studies demonstrating improvements in re-
nal survival in recent years [10]. Means and standard
deviations for the other phenotypes in the clinically eval-
uated subjects are shown in Table 2. All of the phenotypes
showed significant age effects. Liver cysts were present in
nearly half (48%) of the patients. Females with ADPKD
tended to have more liver cysts than males, but these
differences did not reach statistical significance in this
population with a mean age of 34 years. Over half (59%)
of the patients were diagnosed with hypertension before
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(46%), after (3%), or at the time of the clinic visit (10%).
The mean age at diagnosis of hypertension was 33 years,
with males on average diagnosed at younger ages (mean
31 years) than females (mean 35 years). There were also
significant gender differences in serum creatinine concen-
tration and renal volume; however, there were no signifi-
cant gender differences in age at onset of ESRD, urinary
protein excretion, or creatinine clearance.
Frequency distributions for the 315 relatives enrolled
in natural history studies are shown in Figure 2, including
duration of follow-up and martingale residuals for age
at diagnosis of hypertension and age at onset of ESRD.
Serum creatinine, creatinine clearance, renal volume, uri-
nary protein excretion, and liver cyst phenotypes were
measured at the time of the clinic visit. Age at diagno-
sis of hypertension was obtained at the time of the clinic
visit and upon follow-up. As mentioned, none of these
relatives were in ESRD at the time of the clinic visit. For
patients who developed ESRD later, the time since the
clinic visit is highlighted on the frequency distribution of
duration of follow-up. Most of the frequency distributions
showed significant skewness and leptokurtosis. Normaliz-
ing transformations reduced skewness, but had a limited
effect on kurtosis. In theory, the hypothesis tests depend
on normality; however, in practice, the dependence de-
creases with increasing sample size. In order to assess
the effects of nonnormality with the current sample size,
the same analyses were applied to data with and without
transformation. The results were remarkably similar, in-
dicating the analyses are robust against deviations from
normality given the large number of patients included in
the study.
Model 1 and model 2 ANOVA
Results for model 1 and model 2 ANOVAs on nor-
malized data are shown in Table 3. When appropriate
(Table 2), age and gender were included as covariates
in the analyses. Model 1 analyses replicate other stud-
ies in which between-family variation was compared to
within-family variation without regard to the relation-
ships between different family members [14–17]. Consis-
tent with the results of those studies, there is significant
evidence for increased variation between families com-
pared to variation within families for age at diagnosis of
hypertension and age of onset of ESRD. We addition-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 2. Frequency distributions of clinical characteristics of 315 subjects with autosomal-dominant polycystic kidney disease (ADPKD) from 83
PKD1 families. Graphs (A) through (F) show data from the subjects’ natural history visits, at which time no subject had reached end-stage renal
failure (ESRD). (A) Serum creatinine concentration 1.5 ± 1.2, median 1.1, range 0.5 to 8.1 mg/dL. (B) Creatinine clearance 83 ± 39, median 85,
range 9 to 186 mL/min/1.73 m2. (C) Renal volume (mean of both kidneys) 671 ± 537, median 509, range 71 to 2651 cm3. (D) Urinary protein
excretion 252 ± 393, median 138, range 17 to 3472 mg/24 hours. (E) Martingale residuals for the age at onset of ESRD (or no ESRD) 0 ± 0.4,
median 0, range –1.9 to 1.0. (F) Martingale residuals for the age at diagnosis of hypertension (or no hypertension) 0 ± 0.7, median 0, range –4.1
to 1.0. (G) Time between each subject’s natural history visit and either reaching ESRD, death without ESRD, or last follow-up without ESRD.
Subjects with ESRD 3.3 ± 2.3, median 3.0, range 0 to 10 years; subjects without ESRD 3.6 ± 4.2, median 2.7, range 0 to 17 years.
Table 3. Results of model 1 and model 2 analyses of variance of
clinical phenotypes for 315 affected relatives from 83 PKD1 families
(age- and gender-corrected)
Model 1 Model 2
Effect (P value) Effect (P value)
Modifier
Phenotype Family Mutation genes
Serum creatinine mg/dL 0.1502 0.7410 0.0045
Creatinine clearance
mL/min/1.73 m2
0.0185 0.3823 0.0126
Urinary protein excretion
mg/24 hours
0.0069 0.2278 0.0059
Renal volume cm3 0.0212 0.2845 0.0042
Presence/absence of liver
cysts
0.0171 0.1999 0.0286
Number of liver cysts 0.0034 0.2103 0.0008
Age at diagnosis of
hypertension (martingale
residuals)
0.0008 0.0787 0.0045
Age of onset of ESRD
(martingale residuals)
0.0026 0.1512 0.0029
ESRD is end-stage renal disease.
ally found evidence for significant between-family phe-
notype differences with respect to creatinine clearance,
urinary protein excretion, renal volume, and the pres-
ence/absence and number of liver cysts, but not for serum
creatinine.
Model 2 analyses focus on the pattern of intrafamil-
ial phenotype differences to determine the contribution
to between-family effects of differences in the nature of
the PKD1 mutation (mutation effects) and differences
in genetic background (modifier effects). Since all mem-
bers of the same family share the same PKD1 mutation,
the characteristics of different PKD1 mutations may con-
tribute to phenotypic differences between families, but
does not contribute to phenotypic differences within fam-
ilies. However, since members of the same sibship share
their genetic background to a greater extent than mem-
bers of different sibships within the same extended family,
modifier alleles contribute to intrafamilial variability in
addition to interfamilial variability.
As shown in Table 3, there was no evidence for differ-
ential effects of different mutations on any of the phe-
notypes studied (i.e., the between-family mean squares
were not significantly higher than the between-sibship
mean squares). On the other hand, inherited modifier
effects were significant (P < 0.05), and in some cases,
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Table 4. Heritability of clinical phenotypes for 315 affected relatives
from 83 PKD1 families (age- and gender-corrected)
Standard
Trait Heritability error P value
Serum creatinine mg/dL 0.183 0.117 0.0476133
Creatinine clearance
mL/min/1.73 m2
0.323 0.111 0.0007320
Urinary protein excretion
mg/24 hours
0.481 0.123 0.0000156
Renal volume cm3 0.427 0.112 0.0000090
Presence/absence of liver cysts 0.569 0.187 0.0007362
Number of liver cysts 0.353 0.111 0.0003161
Age at diagnosis of hypertension
(truncated sample)a
0.462 0.179 0.0045690
Age at diagnosis of hypertension
(martingale residuals)b
0.585 0.139 0.0000031
Age of onset of ESRD (truncated
sample)a
0.499 0.297 0.0503910
Age of onset of ESRD
(martingale residuals)b
0.434 0.153 0.0013154
ESRD is end-stage renal disease.
aAnalyses restricted to 185 patients with hypertension or 61 patients with
ESRD.
bAnalyses applied to all of 315 affected relatives with clinical data with
event-free relatives assigned a score based on their age.
highly significant (P < 0.01) (i.e., the between-sibship
mean squares were significantly higher than the within-
sibship mean squares). Therefore, the pattern and extent
of intrafamilial variation is more likely explained by dif-
ferences in genetic background than by differences in the
PKD1 mutation. However, when the additional 389 fam-
ily members without clinical evaluation were added to
the analysis of age of onset of ESRD, mutation effects
were highly significant (P < 0.0005), but there was also
evidence for modifier gene effects (P < 0.04).
Heritability
Results of heritability analyses on normalized data
are shown in Table 4. An implicit assumption of these
analyses is that variation in genetic background is the
primary factor in determining phenotype differences be-
tween families. Results of model 2 analyses (Table 3) sup-
port this assumption. The main purpose of heritability
analyses in this context is to estimate the proportion of
the total phenotypic variability in PKD1 that can be at-
tributed to variation in inherited modifiers. The estimates
of heritability were obtained by fitting a model in which
the phenotypic covariance between pairs of relatives is
expressed as a function of their kinship coefficient, or
the expected proportion of alleles they share on average
across the entire genome [40]. For example, the kinship
coefficient between pairs of siblings is 1/2 and the kinship
coefficient between pairs of cousins is 1/8. Using quanti-
tative genetics theory, it can be shown that the phenotypic
covariance between siblings is equal to 1/2 of the genetic
variance, and the phenotypic covariance between cousins
is equal to 1/8 of the genetic variance.
The pattern of the heritability estimates (Table 4) for
different phenotypes corresponds closely to the signifi-
cance levels in model 1 analyses in Table 3, with serum
creatinine showing less evidence for genetic background
effects compared to other phenotypes. The similarity in
the results of the two analyses is expected since both anal-
yses are tests of between-family phenotype differences.
However, by incorporating the precise genetic relation-
ships between members of the same family, the preci-
sion and statistical power of the heritability analyses is
increased in comparison to the model 1 analyses. All of
the phenotypes showed significant (P < 0.05) heritabil-
ity, confirming that one or more modifier genes in the
genetic background accounts for a significant fraction of
the phenotypic variability seen in patients with a muta-
tion in PKD1. The estimated contribution of the genetic
background to the observed variation, as measured by
the heritability estimates, was as follows: serum creati-
nine (18%), creatinine clearance (32%), number of liver
cysts (35%), renal volume (43%), and urinary protein ex-
cretion (48%). The highest heritabilities were seen for the
presence/absence of liver cysts (57%), age at diagnosis of
hypertension (46% and 59%), and age at onset of ESRD
(50% and 43%). Heritability estimates obtained from
analyses with all 315 PKD1-affected relatives scored us-
ing martingale residuals for age at diagnosis of hyperten-
sion and age at onset of ESRD did not differ significantly
from the estimates obtained from analyses in which rela-
tives who had not developed hypertension or ESRD were
excluded. However, the increased power of the analyses
of the complete sample (martingale residuals) is apparent
from the lower standard errors and improved significance
levels compared to the results for the truncated sample.
DISCUSSION
The interfamilial and intrafamilial phenotypic variabil-
ity in PKD1 is poorly understood. Many studies have re-
ported extensive interfamilial phenotypic variability for
hypertension and progression to ESRD [11–14]. In ad-
dition to confirming these results, we found significant
between-family differences in preclinical markers and
liver cysts in 315 PKD1 patients without ESRD (Table 3,
model 1). Either or both of two hypotheses could ex-
plain these results. One hypothesis is that the phenotype
depends on the nature of the PKD1 mutation, which
typically differs in different families (Table 3, model 2,
mutation effects). This would explain phenotypic differ-
ences between families, but would not explain pheno-
typic differences within families, since all members of the
same family share the same mutation. Another hypothe-
sis is that inherited modifiers in the genetic background,
which differ both between and within families, modulate
the expression of the PKD1 mutation (Table 3, model
2, modifier gene effects). This would explain phenotypic
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differences within families in addition to phenotypic dif-
ferences between families. The two hypotheses are not
mutually exclusive (i.e., the renal and extrarenal mani-
festations and severity of PKD1 could depend on both
the mutation and the genetic background).
We found significant evidence that inherited modi-
fiers in the genetic background are major factors in
the intrafamilial and interfamilial phenotypic variability
in preclinical manifestations, complications, and sever-
ity of PKD1. Specifically, our results demonstrate that
phenotypic variability between patients with the same
mutation and different genetic backgrounds (remote rel-
atives; between-sibships mean square) is significantly
increased in comparison to patients with the same mu-
tation and a more similar genetic background (siblings;
within-sibships mean square). Our results also show that
phenotypic variability among patients with different mu-
tations and different genetic backgrounds (unrelated pa-
tients; between-family mean square) was not significantly
different in comparison to patients with the same muta-
tion and different genetic backgrounds (remote relatives;
between-sibships mean square) for most phenotypes.
The majority of PKD1 mutations encode a truncated
polycystin-1 protein [18, 19, 41–43], the functional con-
sequences of which are largely unknown, although there
is indirect evidence that the manifestations and/or sever-
ity of PKD1 may depend on the length of the truncated
protein [18–20]. In one study [19], progression to ESRD
was more rapid in patients with mutations at the 5′ end
of the gene compared to patients with mutations at the
3′ end of the gene, suggesting a truncated polycystin-1
protein may retain some residual function, depending on
its length. However, consistent with our results (Table 3,
model 2) the magnitude of the difference was small (me-
dian time to ESRD 53 and 56 years for 5′ and 3′ mutations)
in relation to the total variation in age at onset of ESRD
(<5% assuming a standard deviation of 10 years), and
in relation to the 5-year difference in median renal sur-
vival between younger and older cohorts from the same
families. Since the study population and source of the
data differed from ours, we replicated their study design
by applying our analyses (model 2) to retrospective and
prospective family history data for renal survival from 704
total living and deceased relatives from 83 PKD1 families
(Table 1). Mutation effects were highly significant (P <
0.0005) in the total group of 704 relatives, but there was
also evidence for modifier gene effects (P < 0.04). Upon
inspection of the family data, we attributed these results
to cohort differences in renal survival combined with a
clustering of older-aged and deceased relatives within a
few large families. However, this would not explain other
evidence for positional effects of PKD1 mutations [19,
20]; and we cannot rule out the possibility that our re-
ported analyses are underpowered for detecting muta-
tion effects, due to the smaller sample size, the young age
of the study population, and relatively short duration of
prospective follow-up (Fig. 2).
The results of heritability analyses indicate the genetic
background contributes 18% to 59% of the total (genetic
and non-genetic) phenotypic variation in renal volume
and function, proteinuria, liver cyst phenotypes, age at
diagnosis of hypertension, and subsequent progression to
ESRD in the study population. It should be emphasized,
however, that these percentages are estimates which must
be viewed with circumspection, as indicated from the high
standard errors (Table 4). In addition, heritability esti-
mates do not allow for similarity between relatives due
to similarities in environment. However, the estimates
appear reasonable in indicating that the genetic back-
ground accounts for a lower fraction of the variability in
serum creatinine (18%) and creatinine clearance (32%)
than is seen for other phenotypes, indicating a stronger
influence of nongenetic factors on these measures in indi-
viduals with relatively normal renal function. Renal vol-
ume displays remarkably high heritability (43%), despite
the well-known limitations of ultrasound for determin-
ing the size and number of renal cysts [44]. The intraclass
correlation coefficient for multiple ultrasound readings
at our institution was 0.86, decreasing to 0.34 for kidneys
greater than 1000 cm3. Nonetheless, renal volume, even
as measured by ultrasound, correlates consistently with
other measures of disease progression [6, 7].
The concept of heritability is widely used in genetics;
however, there is often confusion about the biologic sig-
nificance of heritability estimates. Heritability analyses
are typically applied to normal variation in quantitative
phenotypes or to susceptibility to common diseases. As
shown in the present study, the same principles can be
applied to estimate the contribution of the genetic back-
ground to phenotypic variability in the manifestations
and severity of PKD1 mutations; however, the interpre-
tation and the strengths and limitations of heritability
analyses remain the same. Most important, heritability
estimates are ratios that often differ between different
populations, between correlated phenotypes, and for the
same phenotype measured at different points in time,
whether or not the underlying genetic pathways and
mechanisms are the same. These differences often, but
not always, reflect differences or changes in nongenetic
factors, which are represented only in the denominator of
the ratio. For example, the somewhat lower heritability of
serum creatinine compared to the heritability of creati-
nine clearance, although not statistically significant, most
likely reflects intra- and interindividual variation in non-
genetic factors such as diet and hydration, which have
a larger effect on serum creatinine than on creatinine
clearance.
The main utility of the heritability estimates (Table 4)
from the present study is in providing important baseline
information about the genetic architecture behind the
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phenotypic expression of PKD1. Heritability estimates
obtained from this study are most useful for assessing
the efficiency of family-based linkage and association
studies to map and identify specific modifier genes that
contribute to phenotypic differences in various mark-
ers of disease progression observed prior to the onset of
ESRD. To date, association studies of candidate modifier
genes, such as the ACE gene, which encodes angiotensin-
converting enzyme (ACE), and the ENOS genes, which
encode endothelial nitric oxide synthase (eNOS), have
met with limited success [45–56]. The conflicting results of
these studies could reflect genetic or other differences in
the populations studied, or the relatively small effects of
these genes in relation to other modifying effects. How-
ever, a more likely explanation is that candidate gene
studies are constrained, on the one hand, by current gaps
in understanding the molecular pathology of PKD1 and
the vast number of potential candidates for inherited
modifiers, and, on the other hand, by current gaps in un-
derstanding the functional significance of allelic varia-
tion in known genes, and by the overwhelming number
of genes that remain uncharacterized in terms of either
allelic variation, structure, or function. Quantitative trait
locus (QTL) linkage mapping is an appealing alterna-
tive to candidate gene association studies in that it does
not require any knowledge of disease pathogenesis or
gene function. Although significant heritability is a pre-
requisite for QTL mapping, the power of the approach is
also dependent on the number of different modifier loci
that contribute to phenotypic variability, the magnitude
and nature of effects at any given locus, and other factors
that cannot be inferred from heritability estimates. Other
considerations may be unique to a particular application,
including the nature of the phenotype and the size and
structure of the families available for study.
There are clear indications favoring QTL mapping in
large PKD1 pedigrees, based primarily on the need to
distinguish PKD1 and PKD2 families prior to analyses.
Beyond this, the power and efficiency of the QTL ap-
proach depends on assumptions about how many differ-
ent modifier loci contribute to the heritable variation in
the phenotypic expression of PKD1, and how large is the
effect at any given locus. Observations of extreme dif-
ferences in the severity of PKD1 among members of the
same family have led other investigators to hypothesize
that phenotypic variation could be explained by one or
a few modifier loci [29]. Our results showing significant
phenotype differences between distant relatives, in rela-
tion to close relatives (Table 3, model 2, modifier effects)
but not in relation to unrelated patients (Table 3, model
2, mutation effects), provide additional support for this
hypothesis.
We used computer simulation to determine the expec-
tations for QTL mapping in 234 relatives from the seven
largest families from our resource (>15 total affected
relatives, families 109, 110, 165, 579, 581, 1313, 1359)
(Table 1), assuming a modifier locus contributes 50% of
the phenotypic variability and assuming a modifier locus
contributes 15% of the phenotypic variability. Based on
500 simulated replicates of these families, it will require
10 to 20 total families and genotype data from 400 to 700
total affected and unaffected relatives to map a modifier
locus that contributes 50% of the phenotypic variabil-
ity. The wide range for the sample size estimates reflects
different assumptions about allele frequencies and geno-
typic effects and considerable variability in linkage out-
comes between different replicates of the same family.
The sample size expectations increase exponentially as
the contribution to phenotypic variability decreases; for
example, it will require 100 to 200 total families with 4000
to 8000 total relatives to map a modifier locus that con-
tributes 15% of the phenotypic variability.
CONCLUSION
The present study has demonstrated that interfamil-
ial and intrafamilial phenotype differences in PKD1 are
substantially influenced by differences in genetic back-
ground, and that inherited modifiers account for an esti-
mated 18% to 59% of the phenotypic variability in PKD1.
Although the nature and size of phenotypic effects of
individual modifier genes remain unclear, the extreme
intrafamilial variability in the phenotypic expression of
PKD1 is consistent with the hypothesis that one or a few
modifier loci have a major effect on the progression and
severity of PKD1. These results, in turn, support other
evidence that a limited number of major genes often ac-
count for a surprisingly large fraction of the variability
in quantitative phenotypes [57–59]. We conclude that the
effects of individual modifier genes may be large enough
to be of clinical significance, and, as such, important
enough to proceed with mapping and identifying specific
modifier genes by QTL linkage analysis and positional
cloning.
The focus on markers of disease progression prior
to the onset of ESRD is especially important in clari-
fying the extent and sources of variability in the sub-
group of subjects most likely to participate in prospective
studies.
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